No­vavax’s trou­bles con­tin­ue as Covid vac­cine mak­er plans an­oth­er $300M+ in cost-cut­ting

No­vavax, which has been reel­ing from a slow roll­out of its Covid-19 vac­cine com­pared to the mR­NA mak­ers, said it will once again cut costs.

Like Pfiz­er, BioN­Tech and Mod­er­na, the Gaithers­burg, MD-based com­pa­ny is ad­just­ing to a world in which the virus turns en­dem­ic and vac­cine up­take isn’t as swift as it was in the ear­ly years of the pan­dem­ic. Now, No­vavax is “pre­pared to ini­ti­ate” more than $300 mil­lion in cost-cut­ting next year to “align com­pa­ny scope and struc­ture with fu­ture Covid-19 mar­ket op­por­tu­ni­ty,” the com­pa­ny said Thurs­day in its third-quar­ter up­date.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER